Reading OMCL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OMCL free→Reading OMCL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OMCL free→NASDAQHealth CareHealth Information ServicesSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong. Earnings quality is robust, and management's track record has been steady. Risk is elevated, and the sector backdrop is a headwind. Compared with sector peers, OMCL is above typical. Peer multiples imply a price about 40% below where it trades (it looks expensive on this basis); the read is expensive, growth-justified. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 8 valuation methods, at three horizons. Current price $39.99. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $40 the market pays 21× p/e — above the 15× p/e peer median but in line with its own 22× history. That premium reflects a durable franchise our peer-anchored $29 fair value understates; treat the 'expensive vs peers' read with low confidence. Analysts: $55–$70. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 38% near-term growth, well above our forecast of about 1%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 7.63x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.41 → $0.47 (+13.0% / 30d). 7 raised, 0 cut, 8 covering analysts.
0 upgrades, 0 downgrades / 30d. 88% of analysts rate Buy.
0 positive, 0 negative / 30d.
Market and fundamentals agree. Analysts are positioned bullishly on a fundamentally strong name.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$176.
How much price usually moves either way.
On a bad day, this stock has moved -$398.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,705.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation label changed from 'full' to 'expensive'.
As of June 15, 2026, the valuation changed and became expensive. The sector backdrop fell, indicating a headwind for the company. Risk also rose, suggesting an elevated level of uncertainty.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: A drop below 10% growth would signal a slowdown in revenue growth for Omnicell.
Confirms:Q2 earnings report shows revenue growth below 10% year over year.
Disproves:Q2 earnings report shows revenue growth at or above 10% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for OMCL yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Amendment to the Omnicell, Inc. 2009 Equity Incentive Plan As described below under
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$55.00 – $70.00 (median $60.00) · 3 analysts · as of 2026-04-29
Looks more expensive than peers.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Technology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
OMCL Omnicell | Above typical Show detailsSector percentile: 97 of 100 | expensive | elevated |
VEEV Veeva Systems | Above typical Show detailsSector percentile: 78 of 100 | full | elevated |
SOLV Solventum | Above typical Show detailsSector percentile: 73 of 100 | fair | moderate |
TEM TEMPUS AI, INC. | Above typical Show detailsSector percentile: 72 of 100 | — | elevated |
DOCS Doximity | Above typical Show detailsSector percentile: 80 of 100 | full | high |
1 material management or governance event in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on increasing revenue growth through strategic initiatives.
Enhance operating income through cost management and efficiency improvements.
Focus on enhancing cash flow from operations to support growth and investment.
Why it matters: Exceeding this guidance would show strong demand for Omnicell's products and services.
Confirms:In Q2 2026, total revenues were over $313 million.
Disproves:In Q2 2026, total revenues were under $307 million.
Why it matters: Going over this number shows better profits and efficiency.
Confirms:In Q2 2026, non-GAAP EBITDA was over $42 million.
Disproves:In Q2 2026, non-GAAP EBITDA was under $37 million.
Why it matters: Strong customer engagement shows that people are using the new Titan XT system.
Confirms:Management says many customers want Titan XT in Q2.
Disproves:Customer engagement for Titan XT does not happen or goes down.
Why it matters: This shows strong cash flow. It helps with important investments and keeps finances stable.
Confirms:Cash flow from operations reported over $60M in Q2.
Disproves:Cash flow from operations reported below $54.5M in Q2.
Why it matters: This would confirm effective cost management and support the goal of improving operating income. It shows progress in financial health.
Confirms:Operating income was over $20M in Q2.
Disproves:Operating income was below $16.9M in Q2.
Why it matters: More product bookings show strong demand and growth for Omnicell's solutions.
Confirms:Total product bookings were over $560 million for 2026.
Disproves:Total product bookings were under $510 million for 2026.
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.